A detailed history of Lynch & Associates transactions in Abb Vie Inc. stock. As of the latest transaction made, Lynch & Associates holds 73,479 shares of ABBV stock, worth $12.9 Million. This represents 3.11% of its overall portfolio holdings.

Number of Shares
73,479
Previous 73,746 0.36%
Holding current value
$12.9 Million
Previous $12.6 Million 14.72%
% of portfolio
3.11%
Previous 2.88%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$163.84 - $199.33 $43,745 - $53,221
-267 Reduced 0.36%
73,479 $14.5 Million
Q2 2024

Aug 06, 2024

BUY
$154.79 - $180.76 $422,731 - $493,655
2,731 Added 3.85%
73,746 $12.6 Million
Q1 2024

Apr 09, 2024

SELL
$159.82 - $182.1 $710,080 - $809,070
-4,443 Reduced 5.89%
71,015 $12.9 Million
Q4 2023

Jan 08, 2024

SELL
$137.6 - $154.97 $194,704 - $219,282
-1,415 Reduced 1.84%
75,458 $11.7 Million
Q3 2023

Oct 24, 2023

BUY
$133.59 - $154.65 $43,683 - $50,570
327 Added 0.43%
76,873 $11.5 Million
Q2 2023

Oct 24, 2023

SELL
$132.51 - $164.9 $166,565 - $207,279
-1,257 Reduced 1.62%
76,546 $10.3 Million
Q2 2023

Jul 13, 2023

SELL
$132.51 - $164.9 $166,565 - $207,279
-1,257 Reduced 1.62%
76,546 $10.3 Million
Q1 2023

Oct 24, 2023

BUY
$144.61 - $166.54 $181,774 - $209,340
1,257 Added 1.64%
77,803 $12.4 Million
Q1 2023

Apr 04, 2023

SELL
$144.61 - $166.54 $279,820 - $322,254
-1,935 Reduced 2.43%
77,803 $12.4 Million
Q4 2022

Oct 24, 2023

BUY
$138.31 - $165.87 $396,258 - $475,217
2,865 Added 3.73%
79,738 $12.9 Million
Q4 2022

Jan 05, 2023

SELL
$138.31 - $165.87 $50,483 - $60,542
-365 Reduced 0.46%
79,738 $12.9 Million
Q3 2022

Oct 03, 2022

SELL
$134.21 - $153.93 $168,836 - $193,643
-1,258 Reduced 1.55%
80,103 $10.8 Million
Q2 2022

Jul 06, 2022

BUY
$137.62 - $174.96 $15,000 - $19,070
109 Added 0.13%
81,361 $12.5 Million
Q1 2022

Apr 08, 2022

SELL
$131.98 - $163.75 $200,345 - $248,572
-1,518 Reduced 1.83%
81,252 $13.2 Million
Q4 2021

Jan 11, 2022

BUY
$107.43 - $135.93 $11,817 - $14,952
110 Added 0.13%
82,770 $11.2 Million
Q3 2021

Oct 12, 2021

BUY
$106.4 - $120.78 $1,596 - $1,811
15 Added 0.02%
82,660 $8.92 Million
Q2 2021

Jul 21, 2021

BUY
$105.21 - $117.21 $6,207 - $6,915
59 Added 0.07%
82,645 $9.31 Million
Q1 2021

Apr 09, 2021

BUY
$102.3 - $112.62 $127,875 - $140,775
1,250 Added 1.54%
82,586 $8.94 Million
Q4 2020

Jan 20, 2021

SELL
$80.49 - $108.67 $38,635 - $52,161
-480 Reduced 0.59%
81,336 $8.72 Million
Q3 2020

Oct 21, 2020

BUY
$85.91 - $100.83 $712,193 - $835,880
8,290 Added 11.27%
81,816 $7.17 Million
Q2 2020

Jul 20, 2020

SELL
$73.37 - $98.18 $81,220 - $108,685
-1,107 Reduced 1.48%
73,526 $7.22 Million
Q1 2020

Apr 28, 2020

SELL
$64.5 - $97.79 $88,752 - $134,559
-1,376 Reduced 1.81%
74,633 $5.69 Million
Q4 2019

Jan 10, 2020

BUY
$72.13 - $90.25 $250,651 - $313,618
3,475 Added 4.79%
76,009 $6.73 Million
Q3 2019

Oct 03, 2019

SELL
$62.98 - $75.72 $77,087 - $92,681
-1,224 Reduced 1.66%
72,534 $5.49 Million
Q2 2019

Jul 19, 2019

SELL
$65.7 - $83.98 $8,738 - $11,169
-133 Reduced 0.18%
73,758 $5.36 Million
Q1 2019

Apr 25, 2019

SELL
$77.14 - $90.79 $71,663 - $84,343
-929 Reduced 1.24%
73,891 $5.96 Million
Q4 2018

Jan 10, 2019

BUY
$77.85 - $96.01 $1.44 Million - $1.78 Million
18,516 Added 32.89%
74,820 $6.9 Million
Q3 2018

Oct 05, 2018

SELL
$88.91 - $98.84 $336,968 - $374,603
-3,790 Reduced 6.31%
56,304 $5.33 Million
Q2 2018

Jul 09, 2018

BUY
$89.78 - $106.23 $93,101 - $110,160
1,037 Added 1.76%
60,094 $5.57 Million
Q1 2018

Apr 06, 2018

SELL
$92.01 - $123.21 $324,059 - $433,945
-3,522 Reduced 5.63%
59,057 $5.59 Million
Q4 2017

Jan 04, 2018

SELL
$89.56 - $98.21 $32,778 - $35,944
-366 Reduced 0.58%
62,579 $6.05 Million
Q3 2017

Oct 18, 2017

BUY
$69.85 - $89.22 $4.4 Million - $5.62 Million
62,945
62,945 $5.59 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Lynch & Associates Portfolio

Follow Lynch & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynch & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Lynch & Associates with notifications on news.